Saccharomyces cerevisiae CNCM I-3856 (probiotic yeast) and IBS pain
What 5 graded rows on saccharomyces cerevisiae cncm i-3856 (probiotic yeast) agree on for IBS pain, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Saccharomyces cerevisiae CNCM I-3856 (probiotic yeast) page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Saccharomyces cerevisiae CNCM I-3856 (probiotic yeast) page, with its PubMed record.
Your question
Saccharomyces cerevisiae CNCM I-3856 (probiotic yeast) and IBS pain
5 rows · 1,693 peopleSplit. 3 rows found an improvement, 1 found no difference and 1 had mixed results.
- BGrade B× 1
- CGrade C× 3
- ∅No effect× 1
- Rows
- 5
- Trials
- 5
- At least: a review without a trial count
- People
- 1,693
- Pooled reviews may count some twice
Where they differ
From the rowsThe best-graded row, grade B, is a randomized trial of 456 people (2022) and found an improvement. 1 row is graded No effect, our grade for adequately powered trials that found no effect.
The row that found no difference was larger: 379 people, against a median of 179 people for the 3 rows that found an improvement.
The row that found no difference ran longer (3 months) than the 3 rows that found an improvement (8 weeks).
Only the 3 rows that found an improvement name women in their population.
1 row with mixed results is left out of this comparison.
The rows
3 improved · 1 no difference · 1 mixed- BGrade BAbdominal pain in constipation-predominant IBS · Improved
RCT · n 456 · 2022 · Adults with irritable bowel syndrome with predominant constipation (IBS-C)
8 × 10^9 CFU/day · 8 weeks
More abdominal-pain responders with the yeast (45.1% vs 33.9%, p = 0.017) and a higher quality-of-life score; the area-under-the-curve pain measure (p = 0.073), stool frequency and stool consistency did not differ.
Row on the Saccharomyces cerevisiae CNCM I-3856 (probiotic yeast) page · PubMed 35979259 (opens PubMed)
- CGrade CAbdominal pain and discomfort in IBS · Improved
RCT · n 179 · 2015 · Adults with IBS (Rome III); 84-88% women
500 mg/day · 8 weeks, then 3-week washout
More abdominal-pain responders in the last 4 weeks (63% vs 47%, p = 0.04; OR 1.88, 95% CI 0.99-3.57). Other symptoms showed only non-significant trends; stool frequency and consistency did not change.
Row on the Saccharomyces cerevisiae CNCM I-3856 (probiotic yeast) page · PubMed 25488056 (opens PubMed)
- CGrade CAbdominal pain and stool consistency as an add-on to standard IBS care · Improved
RCT · n 100 · 2020 · Newly diagnosed adults with IBS (diarrhea, constipation and mixed subtypes), Chennai, India
2 × 10^9 CFU twice daily, added to standard care · 8 weeks
Abdominal pain fell more than with placebo, and stool consistency improved in the diarrhea subgroup (p < 0.001), with similar changes in the other subgroups. No serious adverse events.
Row on the Saccharomyces cerevisiae CNCM I-3856 (probiotic yeast) page · PubMed 31807856 (opens PubMed)
- ∅No effectAbdominal pain and discomfort across IBS subtypes · No difference
RCT · n 379 · 2016 · Adults with IBS of all subtypes
1,000 mg/day · 12 weeks
No overall benefit on the primary responder endpoint, symptoms or wellbeing. In the constipation subgroup, abdominal pain and bloating improved vs placebo (subgroup finding needing confirmation).
Row on the Saccharomyces cerevisiae CNCM I-3856 (probiotic yeast) page · PubMed 27403301 (opens PubMed)
- CGrade CPooled abdominal pain and bloating in IBS · Mixed
Meta-analysis · n 579 · 2017 · Individual data from the 2015 and 2016 IBS trials
500-1,000 mg/day · 8-12 weeks
Abdominal pain/discomfort was 12.3% lower than placebo during the second month (p = 0.013) and stool consistency improved, but symptom scores did not differ between groups at the end of supplementation.
Row on the Saccharomyces cerevisiae CNCM I-3856 (probiotic yeast) page · PubMed 28127207 (opens PubMed)